Pure Biologics Spólka Akcyjna (PUR) — Cash Flow-to-Debt Ratio
Pure Biologics Spólka Akcyjna (PUR) has a Cash Flow-to-Debt Ratio of -0.01x as of September 2025, meaning its operating cash flow of zł-216.00K could theoretically repay 0% of its total liabilities (zł20.72 Million) in one year. Explore investment intensity of Pure Biologics Spólka Akcyjna to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Pure Biologics Spólka Akcyjna Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Pure Biologics Spólka Akcyjna across 9 annual periods. Also explore Pure Biologics Spólka Akcyjna asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Pure Biologics Spólka Akcyjna (2016–2024)
Year-by-year debt coverage analysis for Pure Biologics Spólka Akcyjna. For market capitalisation and broader financial context, see Pure Biologics Spólka Akcyjna (PUR) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (PLN) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.70x | zł-10.83 Million | zł15.46 Million | ▲ +37.2% |
| 2023 | -1.12x | zł-23.26 Million | zł20.84 Million | ▲ +5.6% |
| 2022 | -1.18x | zł-17.39 Million | zł14.71 Million | ▲ +62.1% |
| 2021 | -3.12x | zł-24.04 Million | zł7.70 Million | ▼ -4933.4% |
| 2020 | -0.06x | zł-1.35 Million | zł21.83 Million | ▼ -116.9% |
| 2019 | 0.37x | zł5.33 Million | zł14.57 Million | ▲ +164.1% |
| 2018 | -0.57x | zł-2.49 Million | zł4.36 Million | ▲ +77.6% |
| 2017 | -2.55x | zł-2.85 Million | zł1.12 Million | ▼ -130.0% |
| 2016 | -1.11x | zł-710.24K | zł640.12K | — |